Scientists from the La Jolla Institute for Allergy & Immunology have discovered a major trigger for the airway remodeling that is one of the consequences of chronic asthma: LIGHT, a member of the tumor necrosis factor family of proteins. Read More
WASHINGTON – After discussing it for the past two years, the FDA has set a due date, Aug. 17, for makers of extended-release and long-acting opioids to come up with a risk evaluation and mitigation strategy (REMS) for their products. Read More
NanoBio Corp., of Ann Arbor, Mich., announced a licensing agreement with the University of Michigan that provides NanoBio with rights to an antigen that has been shown to prevent urinary tract infections (UTIs) by eliminating E. coli bacteria in the urinary tract following intranasal vaccination. NanoBio said it plans to pair the UTI antigen with the company's nanoemulsion-based NanoStat adjuvant technology as the intranasal delivery mechanism for the vaccine. Read More
Baxter International Inc., of Deerfield, Ill., will acquire Prism Pharmaceuticals Inc., of King of Prussia, Pa., for a total consideration of $338 million. Read More
Marina Biotech Inc., of Bothell, Wash., completed enrollment of its first cohort in its START-FAP Phase Ib/IIa trial of CEQ508, an attenuated bacteria engineered to deliver shRNA, for familial adenomatous polyposis. The cohort of three patients will receive the lowest dose as a daily drink for 28 days. Read More
